Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -2% Improvement Relative Risk HCQ for COVID-19  Rivera et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 506 patients in the USA No significant difference in mortality c19hcq.org Rivera et al., Cancer Discovery, July 2020 Favors HCQ Favors control

Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Rivera et al., Cancer Discovery, doi:10.1158/2159-8290.CD-20-0941
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
Retrospective cancer patients, showing adjusted OR 1.03 [0.62-1.73] for HCQ. The study reports the number of HCQ+AZ patients but they do not provide results for HCQ+AZ (only HCQ + any other treatment). Significant confounding by indication and compassionate use is likely.
risk of death, 2.4% higher, RR 1.02, p = 0.92, treatment 44 of 179 (24.6%), control 59 of 327 (18.0%), adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rivera et al., 22 Jul 2020, retrospective, USA, peer-reviewed, 45 authors.
This PaperHCQAll
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Donna R Rivera, Solange Peters, Orestis A Panagiotou, Dimpy P Shah, Nicole M Kuderer, Chih-Yuan Hsu, Samuel M Rubinstein, Brendan J Lee, Toni K Choueiri, Gilberto De Lima Lopes, Petros Grivas, Corrie A Painter, Brian I Rini, Michael A Thompson, Jonathan Arcobello, Ziad Bakouny, Deborah B Doroshow, Pamela C Egan, Dimitrios Farmakiotis, Leslie A Fecher, Christopher R Friese, Matthew D Galsky, Sanjay Goel, Shilpa Gupta, Thorvardur R Halfdanarson, Balazs Halmos, Jessica E Hawley, Ali Raza Khaki, Christopher A Lemmon, Sanjay Mishra, Adam J Olszewski, Nathan A Pennell, Matthew M Puc, Sanjay G Revankar, Lidia Schapira, Andrew Schmidt, Gary K Schwartz, Sumit A Shah, Julie T Wu, Zhuoer Xie, Albert C Yeh, Huili Zhu, Yu Shyr, Gary H Lyman, Jeremy L Warner
Cancer Discovery, doi:10.1158/2159-8290.cd-20-0941
Among 2,186 U.S. adults with invasive cancer and laboratory-confi rmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical signifi cance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our fi ndings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials. SIGnIfICAnCE: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically signifi cant 30-day all-cause mortality benefi t with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefi t. Treatment receipt refl ects clinical decision-making and suggests disparities in medication access.
Authors' Contributions
References
Adamsick, Gandhi, Bidell, Elshaboury, Bhattacharyya et al., Remdesivir in patients with acute or chronic kidney disease and COVID-19, J Am Soc Nephrol
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of Covid-19-preliminary report, N Engl J Med
Burton, Fort, Seoane, Hospitalization and mortality among black patients and white patients with Covid-19, N Engl J Med
Chowkwanyun, Reed, Racial health disparities and Covid-19-caution and context, N Engl J Med
Collins, Bowman, Landray, Peto, The magic of randomization versus the myth of real-world evidence, N Engl J Med
Core, R: A language and environment for statistical computing
Desai, Warner, Kuderer, Thompson, Painter et al., Crowdsourcing a crisis response for COVID-19 in oncology, Nat Cancer
Dyall, Coleman, Hart, Venkataraman, Holbrook et al., Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection, Antimicrob Agents Chemother
Friedman, Hastie, Tibshirani, Regularization paths for generalized linear models via coordinate descent, J Stat Softw
Garassino, Whisenant, Huang, Trama, Torri et al., COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study, Lancet Oncol
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Gehlenborg, UpSetR: a more scalable alternative to Venn and Euler diagrams for visualizing intersecting sets
Goldman, Lye, Hui, Marks, Bruno et al., Remdesivir for 5 or 10 days in patients with severe Covid-19, N Engl J Med
Grein, Ohmagari, Shin, Diaz, Asperges et al., Compassionate use of remdesivir for patients with severe Covid-19, N Engl J Med
Griffith, Morris, Tudball, Herbert, Mancano et al., Collider bias undermines our understanding of COVID-19 disease risk and severity, medRxiv
Guaraldi, Meschiari, Cozzi-Lepri, Milic, Tonelli et al., Tocilizumab in patients with severe COVID-19: a retrospective cohort study, Lancet Rheum
Harrell, Lee, Mark, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Stat Med
Harrell, R Foundation for Statistical Computing
Harrell, RMS: Regression modeling strategies
Ho, Imai, King, Stuart, MatchIt: nonparametric preprocessing for parametric causal inference, J Stat Softw
Khalatbari-Soltani, Cumming, Delpierre, Kelly-Irving, Importance of collecting data on socioeconomic determinants from the early stage of the COVID-19 outbreak onwards, J Epidemiol Community Health
Kuderer, Choueiri, Shah, Shyr, Rubinstein et al., Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, Lancet
Lee, Cazier, Starkey, Turnbull, Kerr et al., COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study, Lancet
Lex, Gehlenborg, Strobelt, Vuillemot, Pfister, UpSet: visualization of intersecting sets, IEEE Trans Vis Comput Graph
Liang, Guan, Chen, Li, Xu, Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol
Mehra, Desai, Kuy, Henry, Patel, Retraction: cardiovascular disease, drug therapy, and mortality in covid-19, N Engl J Med
Mehra, Ruschitzka, Patel, Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet
Mehta, Goel, Kabarriti, Cole, Goldfinger et al., Case fatality rate of cancer patients with COVID-19 in a New York hospital system, Cancer Discov
Nipp, Hong, Paskett, Overcoming barriers to clinical trial enrollment, Am Soc Clin Oncol Educ Book
Recovery Collaborative Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in hospitalized patients with covid-19-preliminary report, N Engl J Med
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area, JAMA
Robin, Turck, Hainard, Tiberti, Lisacek et al., pROC: an open-source package for R and S+ to analyze and compare ROC curves, BMC Bioinform
Rubinstein, Steinharter, Warner, Rini, Peters et al., The COVID-19 and cancer consortium: a collaborative effort to understand the effects of COVID-19 on patients with cancer, Cancer Cell
Russell, Millar, Baillie, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet
Salas, Hofman, Stricker, Confounding by indication: an example of variation in the use of epidemiologic terminology, Am J Epidemiol
Sheahan, Sims, Leist, Schäfer, Won et al., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat Commun
Skipper, Pastick, Engen, Bangdiwala, Abassi et al., Hydroxychloroquine in nonhospitalized adults with early COVID-19, Ann Int Med
Spring, Md, FDA
Spring, Md, None, FDA
Tian, Yuan, Xiao, Zhong, Yang et al., Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study, Lancet Oncol
Tingley, Yamamoto, Hirose, Keele, Imai, mediation: R package for causal mediation analysis, J Stat Softw
Van Der Pas, Scott, Chakraborty, Bhattacharya, Horseshoe: implementation of the horseshoe prior
Williamson, Walker, Bhaskaran, Bacon, Bates et al., OpenSAFELY: factors associated with COVID-19 death in 17 million patients, Nature
Yancy, COVID-19 and African Americans, JAMA
Yang, Sheng, Huang, Jin, Xiong et al., Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study, Lancet Oncol
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Yu, Ouyang, Chua, Xie, SARS-CoV-2 Transmission in patients with cancer at a tertiary care hospital in Wuhan, China, JAMA Oncol
Zhang, Zhu, Xie, Wang, Wang et al., Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China, Ann Oncol
Zimmermann, Ziesenitz, Curtis, Ritz, The Immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms, Front Immunol
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit